Dendritic Cells: Master Regulators of the Immune Response

Ira Mellman

Abstract

Dendritic cells (DC) are responsible for initiating all antigen-specific immune responses. As such, they are the master regulators of the immune response and serve this function by linking the microbial sensing features of the innate immune system to the exquisite specificity of the adaptive response. They are exceptionally efficient at antigen presentation and also adept at generating just the right type of T cells in response to a given pathogen. Importantly, DCs also help guide the immune system to respond to foreign antigens while avoiding the generation of autoimmune responses to self. DCs are thus paradoxically important in cancer, generating both immunity and tolerance. Given their central role in controlling the immune response in patients with cancer, DCs are emerging as a critical cell type that must be considered as we come to understand basic cancer immunobiology. They should also be considered as potential targets or at least as key players in any effort intended to generate therapeutic vaccines. Cancer Immunol Res; 1(3); 145–9. ©2013 AACR.


Disclosure of Potential Conflicts of Interest

I. Mellman is employed as a Vice President at Genentech, which also provides his laboratory with research support.

CME Staff Planners’ Disclosures

The members of the planning committee have no real or apparent conflict of interest to disclose.

Learning Objectives

Upon completion of this activity, the participant should understand the critical roles of dendritic cells in guiding host immune responses, and the details of how they mature, process, and present antigens. Understanding the paradoxical importance of dendritic cells in immunity and tolerance will inform the development of successful cancer immunotherapies.

Acknowledgment of Financial or Other Support

This activity does not receive commercial support.

Introduction

The immune system is divided into two basic elements, a conceptual understanding that dates back to the early days of the 20th century. The cellular or innate immune system was first described by the pathologist Elie Metchnikoff who recognized the existence of cells in the blood and tissues whose role was to identify, capture, and destroy invading pathogens. These cells, including macrophages and neutrophils, were found to provide a rapid response to virtually all pathogens and to initiate inflammation at sites of local infection. The adaptive immune system, discovered by Paul Ehrlich, involves the production of circulating antibodies that can provide long lasting, systemic immunity that is specific to antigens expressed by a given pathogen. We now understand that adaptive immunity is the purview of a second set of leukocytes, T and B lymphocytes, which are responsible not only for antibody production but also for the generation of T cells that can directly identify and kill host cells infected by pathogens (e.g., viruses). In addition to the involvement of distinct cell types, the key conceptual difference between innate and adaptive immunity is their distinct modes of pathogen detection: cells of the innate system are equipped to take action rapidly by detecting biochemical determinants shared by wide arrays of pathogens, whereas cells of the adaptive immune system generate antigen-specific protection that takes longer to develop but is provided with a memory component that can last a lifetime.

It has long been appreciated that the innate and adaptive arms of the immune system must be coordinated, but it was not until the discovery of dendritic cells (DC) by Ralph Steinman at The Rockefeller University in the early 1980s that we truly understood conceptually how the immune system functions as a coherent unit. Like cells of the innate immune system, DCs detect invading pathogens due to their expression of a variety of sensors for pathogen-derived components either
on the plasma membrane (e.g., Toll-like receptors, TLR) or in the cytosol (e.g., NOD-like receptors). Rather than serving to directly destroy pathogens, DCs take a far more sophisticated approach. They act to communicate the presence of pathogens to the adaptive immune system thereby initiating long lasting, antigen-specific responses. DCs accomplish this function by carefully marshalling the proteolytic apparatus in both the endosomal–lysosomal system (cathepsins and other lysosomal hydrolases) as well as in the cytosol (proteasome) and endoplasmic reticulum (ER) to partially degrade pathogen-derived proteins to yield antigenic peptides that in turn are loaded onto MHC class I or class II molecules. The resulting peptide–MHC complexes are transported to the plasma membrane where they are presented to their cognate T cells that are then activated and induced to proliferate and become potent effector cells (cytotoxic T cells) or cells that assist in the overall progress of the immune responses (helper T cells). T-cell responses are further enhanced and sculpted by the fact that DCs also express ligands (e.g., CD80, CD86) that bind to costimulatory molecules on T cells that act in concert with the peptide–MHC–specific T-cell receptor. Importantly, DCs also produce a host of stimulatory cytokines [e.g., interleukin-12 (IL-12)] that are required for optimal T-cell stimulation. Although other cell types (e.g., macrophages, B cells) can present antigen, due to their remarkable efficiency, DCs are uniquely responsible for initiating all antigen-specific immune responses. Indeed, DCs can even stimulate B cells directly by presenting intact antigen at the DC surface thereby activating B cells of cognate specificity. Importantly, DCs are also charged with maintaining immune tolerance by ensuring under normal conditions that effector T cells are not produced against the normal or “self” antigens of host cells and tissues. In the absence of infection, that is, at the steady state, DCs continuously encounter and present self-antigens and nonpathogenic environmental antigens to T cells. Under these conditions, effector T cells are not induced to proliferate, but rather, the production of immunosuppressive regulatory T cells (Tregs) is favored. These “induced” Tregs, as opposed to the naturally occurring Tregs produced in the thymus, also help to prevent unwanted immune responses against noninfectious environmental antigens entering via the gut and airway. How DCs initiate immunity against foreign antigens while maintaining tolerance to self-antigens is both a paradox and central to understanding DC function. In cancer, as most tumors are far more similar than not to normal cells and are often likely to initiate in the absence of overt inflammation, the ability of DCs to induce peripheral tolerance likely represents a major constraint against the generation of antitumor immunity.

**DC maturation**

DCs derive their efficiency at antigen presentation and T-cell stimulation from a series of specializations that enhance their overall function. Yet, these specializations do not appear to involve the expression of many, or even any, DC-specific gene products in the fashion of B cells uniquely expressing immunoglobulin receptors or T cells expressing T-cell receptors. Rather, DCs seem to excel by carefully optimizing and regulating an array of properties they share with a variety of cells in the immune system. Although this has classically made DCs difficult to study and to differentiate from other cells, detailed investigation of their function and lineage has proved DCs to represent a distinct if heterogeneous cell type (1).

A key DC specialization is their ability to exist in two functionally distinct states: immature and mature (2). Immature DCs are generally found in peripheral tissues where they patrol for invading pathogens and dying host cells. As immature DCs are highly adept at endocytosis, particularly macrophagocytosis and phagocytosis, they can accumulate large quantities of soluble and cell-bound antigens. A hallmark of immature DCs is their relative inability to present the antigens they accumulate to T cells. Although they synthesize both MHC class I and class II molecules, immature DCs are relatively inefficient at generating peptide-MHC complexes at the plasma membrane. Lysosomal protease activity is attenuated, reducing the formation of antigenic peptides. In addition, MHC class II molecules are actively diverted to lysosomes during their biogenesis due at least in part to ubiquitination, further limiting the accumulation of peptide-loaded complexes at the surface. Immature DCs also secrete very few immunostimulatory cytokines and poorly express ligands for costimulatory molecules.

Upon encountering pathogen-derived TLR ligands, ligands for intracellular sensors, or proinflammatory molecules, immature DCs are triggered to mature, which converts them in 12 to 24 hours from cells adept at antigen accumulation to cells now specialized for T-cell stimulation. After a transient upregulation (presumably to increase the opportunity to capture the newly arrived pathogen), endocytosis is dramatically down regulated. Lysosomes and the antigen-processing machinery are activated, enhancing the efficiency of peptide-MHC production. Ubiquitination of MHC class II and other molecules ceases, allowing peptide-MHC complexes to remain at the cell surface. Next, they are induced to migrate from tissues to lymphoid organs, in part by upregulating chemokine receptors such as CCR7, begin to efficiently generate peptides that can be loaded stably onto MHC molecules, and upregulate the production of costimulatory ligands and immunostimulatory cytokines. They enter T-cell–rich regions of lymph nodes and begin to stimulate antigen-specific memory or naive T-cell responses (3, 4).

Although the basic features of maturation that enhance the DCs’ antigen-presentation capacity are fairly well understood, the maturation program itself is more sophisticated. Depending upon the type of pathogen encountered, and therefore the types of TLR ligands and other maturation signals received, DCs can exhibit qualitatively different maturation pathways that will result in qualitatively different T-cell outcomes. In other words, DCs not only stimulate T cells but can polarize the nature of the T-cell response (e.g., Th1 vs. Th2 T-cell production) depending on immunologic need (e.g., Toxoplasma vs. Schistosoma infections, respectively; Fig. 1). DCs thus interrogate, interpret, and then transmit the nature of the pathogenic stimulus to guide the immune response. In addition, it seems increasingly likely that some form of maturation signal can be received even in the absence of overt infection, i.e., at the steady
Such signals may enhance the DC's ability to present self-antigen to promote tolerance and elicit the production of Tregs; alternatively, unstimulated, immature DCs may carry out this function. The mechanisms underlying these events are currently under active investigation as they will likely prove keys to understanding how DCs may act to restrict protective T-cell responses in cancer, and also how they might be mobilized for therapeutic benefit. In this context, it is worth emphasizing that “adjuvants” used during any vaccination procedure are little more than DC maturation signals.

The basic pathways of antigen processing are well understood, although many important details remain poorly described (Fig. 2). MHC class II pathway is most commonly associated with the presentation of antigens derived from extracellular sources. Antigens such as bacteria, protozoans, allergens, or dead cells are internalized by endocytosis and delivered to one or more populations of endosomes and lysosomes where they encounter environments of progressively decreasing pH and increasing hydrolytic activity. In DCs, especially immature DCs, MHC class II molecules are delivered to most of the same compartments. Here, the antigens are denatured and partially cleaved revealing domains capable of binding to MHC class II. Unbound regions of these protein antigens are then removed by exo-proteases leaving a 10-15-mer peptide bound to the MHC class II binding cleft. Upon maturation, these peptide–MHC complexes are transferred to the surface, or are routed there constitutively if formed after maturation.

As mentioned above, the MHC class I pathway is typically associated with the presentation of peptides derived from endogenously synthesized components, such as viral proteins made in the cytoplasm of infected cells. In this example, a fraction of newly synthesized viral proteins are ubiquitinated, cleaved by the proteasome, and the resulting peptides translocated into the ER via the TAP1/TAP2 ATP-dependent
peptide transporter for loading on to MHC class I molecules in the ER lumen. Peptide loading completes the folding process, rendering the MHC class I-peptide complexes competent for transport from the ER to the Golgi complex and finally to the plasma membrane. DCs are peculiarly capable of a variation of this process that allows extracellular antigens also to enter the endogenous MHC class I pathway. This variation, cross presentation, allows antigens internalized by endocytosis to escape across the endosomal, phagosomal, or lysosomal membrane and to become substrates for the cytosolic processing machinery (there is some evidence that the relevant population of MHC class I molecules used for loading may be in endosomal compartments in addition to the ER; Fig. 2). How antigen escapes endosomes is unclear, but may simply reflect a controlled rupture of the endosomal-phagosomal membrane. DCs could excel in cross presentation relative to other cells by enhancing the rate of rupture or by attenuating the rate at which internalized antigens are destroyed before reaching the cytosol; there is evidence that both mechanisms are at work.

Importantly, antigens presented by both the MHC class I and class II systems play a role in generating immunity and maintaining tolerance depending on the maturation or activating state of the DCs engaged in presentation.

DCs exist as multiple populations

While most or all DCs may share the phenotypic features associated with maturation and antigen presentation, it is also clear that they exist as multiple subpopulations both in human and in mouse (1). The relationships among these various subsets are just being worked out based on detailed lineage analysis. Most DCs are directly or indirectly derived from bone marrow precursors, with tissue (including lymphoid organ) residents and circulating DCs being derived from common early progenitors while new DCs recruited from the blood especially in response to inflammation can be differentiated by cytokines (e.g., GM-CSF and IL-4) from monocytes. Langerhans cells, the DCs of the epidermis, may expand by local proliferation or derive from progenitors housed in the hair follicle. Plasmacytoid DCs (pDC) represent another distinctive subset as compared with "conventional" DCs (cDC) that share myeloid or monocytic progenitors. pDCs diverge from cDCs at an early stage of development and are quite distinct in their ability to react to virus infection by the production of prolific amounts of type I interferons. Like other DCs, though, they do retain at least some capacity for antigen presentation.

Although interesting, the origin and development of diverse DC subsets is less important than their functional implications. Indeed, there is increasing evidence that different populations found even within a single peripheral organ (skin, gut, lung) can have decidedly different functions in inflammation, generating polarized T-cell responses, or the regulation of immunity (4). These differences likely reflect divergence of DCs at late stages development, or even at the stage of maturation. They are not likely to reflect the existence of distinct cell types with fundamentally different or hard-wired properties. Unfortunately, DC subsets are generally defined on the basis of surface markers that have little if anything at all to do with their
functions, making them difficult to study or to understand at the molecular level.

One of the most intriguing properties of subsets concern variations in their capacity for cross presentation on MHC class I. In the mouse, cDCs expressing CD8α in the spleen and lymph nodes are rare populations that both in vivo and in vitro are more efficient at cross presentation than their more numerous CD8α-negative counterparts. Development of these cells seems to be under the control of the Batf and IRF8 transcription factors. However, no unique transcripts have yet been identified that explain their enhanced capacity for cross presentation; rather, the increased efficiency may reflect a series of small as yet incompletely identified optimizations. In contrast, the CD8α-negative population may be relatively more adept at presentation on MHC class II, although in vitro and likely in vivo under conditions of antigen excess, both populations can mediate both forms of antigen presentation.

In humans, the BDCA3-positive subset (relative to the more numerous BDCA1 subset) has been associated with greater cross presentation capacity, but again as in the mouse, this is a question of degree and not of absolute ability (5).

DCs, cancer, and cancer immunotherapy

The fact that many patients with cancer make objective T-cell responses to their tumors indicates that at some point DCs must have successfully presented one or more tumor-associated antigens to naïve T cells. On the other hand, due to the similarity of many tumor antigens (including proteins bearing point mutations) to normally occurring self-proteins as well as to their chronic exposure to DCs under noninflammatory conditions, antigen presentation by tumor-exposed DCs may just as easily serve to induce tolerance, likely by the generation of Tregs. Furthermore, as a tumor progresses, potent mechanisms of immunosuppression can develop that potently inhibit the function of effector T cells. Some of these can be induced in DCs by factors in the tumor microenvironment, perhaps derived from other infiltrating myeloid cells. Such mechanisms can include the expression of PD-L1 and PD-L2 (ligands for T-cell checkpoint receptor Programmed-Death-1 (PD-1), which induces T-cell *exhaustion*), TGFβ (favors Treg production), and cytotoxic enzymes such as indoleamine-2,3-dioxygenase and arginase (that generate immunosuppressive metabolites). Although as yet poorly characterized mechanistically, it is becoming clear that tumors help ensure their resistance to immune recognition by limiting both T-cell and DC function.

The suppression of DC activity, especially in the absence of optimal adjuvants and antigen delivery systems, helps explain why vaccine therapies in cancer have not yet proved efficacious (6). Moreover, even if antitumor T cells had been produced as a consequence of vaccination, their activities would likely be subverted by immunosuppression in the tumor bed. In contrast, therapies that target T-cell checkpoints or nodes of immune suppression (anti-CTLA4, anti-PD-1, anti-PD-L1) have exhibited exciting activity, in the first instance by rescuing pre-existing T-cell responses. Used in conjunction with such immunomodulators, the prospects for cancer vaccines as adding to a combination regimen of immunotherapy appear both biologically rational and therapeutically tractable. Such approaches will require not only careful attention paid to the problem of antigen selection, but also, and most importantly from the vantage point of this brief review, to the issue of adjuvants: what DC maturation signals will facilitate the generation of activated DCs most capable of eliciting antitumor T-cell responses? The optimal adjuvant should favor the production of cytotoxic CD8+ T cells. Therefore, it seems reasonable to imagine that adjuvants derived from pathogens that do this in nature (e.g., viruses) might accomplish this task in the therapeutic setting. Alternatively, even synthetic adjuvants that upregulate DC surface proteins known to favor polarization to CD8+ T cells (e.g., CD70) might also suffice. As we learn more about the basic biology of DCs, we become substantially better informed as to the steps we can or should take in the therapeutic setting to recruit their participation in enhancing the type of durable responses to cancer we can now expect from successful immunotherapies.

Received July 19, 2013; accepted July 22, 2013; published online September 9, 2013.

References
